Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
67
GLUE Quote, Financials, Valuation and Earnings
Last price:
$17.24
Seasonality move
:
6.72%
Day range:
$16.57 - $17.63
52-week range:
$3.50 - $17.63
Dividend yield:
0%
P/E ratio:
56.52x
P/S ratio:
7.35x
P/B ratio:
4.57x
Volume:
659.2K
Avg. volume:
1M
1-year change:
86.8%
Market cap:
$1.1B
Revenue:
$75.6M
EPS (TTM):
$0.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GLUE
Monte Rosa Therapeutics, Inc.
|
$7.4M | -$0.35 | -74.43% | -21.17% | $17.20 |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$37.8M | -$0.28 | 50.99% | -69.07% | $22.25 |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$130.5M | -$0.16 | 36.52% | -85.85% | $87.99 |
|
NAOV
NanoVibronix, Inc.
|
-- | -- | -- | -- | -- |
|
NVS
Novartis AG
|
$13.9B | $2.31 | 4.45% | 37.94% | $134.88 |
|
RCEL
AVITA Medical, Inc.
|
$18M | -$0.29 | -5.31% | -22.01% | $7.92 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GLUE
Monte Rosa Therapeutics, Inc.
|
$17.26 | $17.20 | $1.1B | 56.52x | $0.00 | 0% | 7.35x |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$8.34 | $22.25 | $856.3M | -- | $0.00 | 0% | 6.40x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$70.99 | $87.99 | $3.6B | -- | $0.00 | 0% | 7.66x |
|
NAOV
NanoVibronix, Inc.
|
$4.10 | -- | $4.5M | -- | $0.00 | 0% | 0.38x |
|
NVS
Novartis AG
|
$133.72 | $134.88 | $256.6B | 18.24x | $3.99 | 2.99% | 4.84x |
|
RCEL
AVITA Medical, Inc.
|
$3.51 | $7.92 | $107M | -- | $0.00 | 0% | 1.30x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GLUE
Monte Rosa Therapeutics, Inc.
|
14.05% | 3.291 | 8.77% | 6.37x |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
0.64% | 0.642 | 0.4% | 8.29x |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
52.19% | 1.763 | 8.47% | 3.01x |
|
NAOV
NanoVibronix, Inc.
|
2.68% | -1.127 | 20.52% | 0.62x |
|
NVS
Novartis AG
|
41.94% | 0.086 | 12.99% | 0.58x |
|
RCEL
AVITA Medical, Inc.
|
117.49% | -1.939 | 28.73% | 0.52x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GLUE
Monte Rosa Therapeutics, Inc.
|
$10.7M | -$33M | 7.34% | 8.6% | -258.26% | $99.8M |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
$35.3M | -$24.3M | -30.8% | -30.98% | -60.94% | -$5.8M |
|
MIRM
Mirum Pharmaceuticals, Inc.
|
$107.4M | $2.6M | -7.32% | -16.73% | 1.96% | $39.5M |
|
NAOV
NanoVibronix, Inc.
|
$189K | -$2.2M | -13.54% | -14.38% | -311.22% | -$2M |
|
NVS
Novartis AG
|
$10.3B | $4.2B | 19.37% | 33.87% | 30.24% | $5.7B |
|
RCEL
AVITA Medical, Inc.
|
$13.9M | -$9.2M | -111.55% | -1112.54% | -53.65% | -$6.5M |
Monte Rosa Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns GLUE or DAWN?
Day One Biopharmaceuticals, Inc. has a net margin of -212.1% compared to Monte Rosa Therapeutics, Inc.'s net margin of -49.57%. Monte Rosa Therapeutics, Inc.'s return on equity of 8.6% beat Day One Biopharmaceuticals, Inc.'s return on equity of -30.98%.
Company Gross Margin Earnings Per Share Invested Capital GLUEMonte Rosa Therapeutics, Inc.83.59% -$0.33 $286M DAWNDay One Biopharmaceuticals, Inc.88.74% -$0.19 $453.8M -
What do Analysts Say About GLUE or DAWN?
Monte Rosa Therapeutics, Inc. has a consensus price target of $17.20, signalling downside risk potential of -0.35%. On the other hand Day One Biopharmaceuticals, Inc. has an analysts' consensus of $22.25 which suggests that it could grow by 166.79%. Given that Day One Biopharmaceuticals, Inc. has higher upside potential than Monte Rosa Therapeutics, Inc., analysts believe Day One Biopharmaceuticals, Inc. is more attractive than Monte Rosa Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLUEMonte Rosa Therapeutics, Inc.5 1 0 DAWNDay One Biopharmaceuticals, Inc.5 1 0 -
Is GLUE or DAWN More Risky?
Monte Rosa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Day One Biopharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GLUE or DAWN?
Monte Rosa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Day One Biopharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monte Rosa Therapeutics, Inc. pays -- of its earnings as a dividend. Day One Biopharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLUE or DAWN?
Monte Rosa Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Day One Biopharmaceuticals, Inc. quarterly revenues of $39.8M. Monte Rosa Therapeutics, Inc.'s net income of -$27.1M is lower than Day One Biopharmaceuticals, Inc.'s net income of -$19.7M. Notably, Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio is 56.52x while Day One Biopharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics, Inc. is 7.35x versus 6.40x for Day One Biopharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLUEMonte Rosa Therapeutics, Inc.7.35x 56.52x $12.8M -$27.1M DAWNDay One Biopharmaceuticals, Inc.6.40x -- $39.8M -$19.7M
-
Which has Higher Returns GLUE or MIRM?
Mirum Pharmaceuticals, Inc. has a net margin of -212.1% compared to Monte Rosa Therapeutics, Inc.'s net margin of 2.18%. Monte Rosa Therapeutics, Inc.'s return on equity of 8.6% beat Mirum Pharmaceuticals, Inc.'s return on equity of -16.73%.
Company Gross Margin Earnings Per Share Invested Capital GLUEMonte Rosa Therapeutics, Inc.83.59% -$0.33 $286M MIRMMirum Pharmaceuticals, Inc.80.75% $0.05 $610.8M -
What do Analysts Say About GLUE or MIRM?
Monte Rosa Therapeutics, Inc. has a consensus price target of $17.20, signalling downside risk potential of -0.35%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $87.99 which suggests that it could grow by 23.95%. Given that Mirum Pharmaceuticals, Inc. has higher upside potential than Monte Rosa Therapeutics, Inc., analysts believe Mirum Pharmaceuticals, Inc. is more attractive than Monte Rosa Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLUEMonte Rosa Therapeutics, Inc.5 1 0 MIRMMirum Pharmaceuticals, Inc.8 0 0 -
Is GLUE or MIRM More Risky?
Monte Rosa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.421, suggesting its less volatile than the S&P 500 by 57.855%.
-
Which is a Better Dividend Stock GLUE or MIRM?
Monte Rosa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monte Rosa Therapeutics, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLUE or MIRM?
Monte Rosa Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Mirum Pharmaceuticals, Inc. quarterly revenues of $133M. Monte Rosa Therapeutics, Inc.'s net income of -$27.1M is lower than Mirum Pharmaceuticals, Inc.'s net income of $2.9M. Notably, Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio is 56.52x while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics, Inc. is 7.35x versus 7.66x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLUEMonte Rosa Therapeutics, Inc.7.35x 56.52x $12.8M -$27.1M MIRMMirum Pharmaceuticals, Inc.7.66x -- $133M $2.9M
-
Which has Higher Returns GLUE or NAOV?
NanoVibronix, Inc. has a net margin of -212.1% compared to Monte Rosa Therapeutics, Inc.'s net margin of 83.1%. Monte Rosa Therapeutics, Inc.'s return on equity of 8.6% beat NanoVibronix, Inc.'s return on equity of -14.38%.
Company Gross Margin Earnings Per Share Invested Capital GLUEMonte Rosa Therapeutics, Inc.83.59% -$0.33 $286M NAOVNanoVibronix, Inc.26.18% -$0.91 $43.6M -
What do Analysts Say About GLUE or NAOV?
Monte Rosa Therapeutics, Inc. has a consensus price target of $17.20, signalling downside risk potential of -0.35%. On the other hand NanoVibronix, Inc. has an analysts' consensus of -- which suggests that it could grow by 81333.23%. Given that NanoVibronix, Inc. has higher upside potential than Monte Rosa Therapeutics, Inc., analysts believe NanoVibronix, Inc. is more attractive than Monte Rosa Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLUEMonte Rosa Therapeutics, Inc.5 1 0 NAOVNanoVibronix, Inc.0 0 0 -
Is GLUE or NAOV More Risky?
Monte Rosa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NanoVibronix, Inc. has a beta of 2.056, suggesting its more volatile than the S&P 500 by 105.553%.
-
Which is a Better Dividend Stock GLUE or NAOV?
Monte Rosa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoVibronix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monte Rosa Therapeutics, Inc. pays -- of its earnings as a dividend. NanoVibronix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLUE or NAOV?
Monte Rosa Therapeutics, Inc. quarterly revenues are $12.8M, which are larger than NanoVibronix, Inc. quarterly revenues of $722K. Monte Rosa Therapeutics, Inc.'s net income of -$27.1M is lower than NanoVibronix, Inc.'s net income of $600K. Notably, Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio is 56.52x while NanoVibronix, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics, Inc. is 7.35x versus 0.38x for NanoVibronix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLUEMonte Rosa Therapeutics, Inc.7.35x 56.52x $12.8M -$27.1M NAOVNanoVibronix, Inc.0.38x -- $722K $600K
-
Which has Higher Returns GLUE or NVS?
Novartis AG has a net margin of -212.1% compared to Monte Rosa Therapeutics, Inc.'s net margin of 28.26%. Monte Rosa Therapeutics, Inc.'s return on equity of 8.6% beat Novartis AG's return on equity of 33.87%.
Company Gross Margin Earnings Per Share Invested Capital GLUEMonte Rosa Therapeutics, Inc.83.59% -$0.33 $286M NVSNovartis AG74.59% $2.02 $76.8B -
What do Analysts Say About GLUE or NVS?
Monte Rosa Therapeutics, Inc. has a consensus price target of $17.20, signalling downside risk potential of -0.35%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could grow by 0.87%. Given that Novartis AG has higher upside potential than Monte Rosa Therapeutics, Inc., analysts believe Novartis AG is more attractive than Monte Rosa Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLUEMonte Rosa Therapeutics, Inc.5 1 0 NVSNovartis AG1 6 2 -
Is GLUE or NVS More Risky?
Monte Rosa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.
-
Which is a Better Dividend Stock GLUE or NVS?
Monte Rosa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 2.99% to investors and pays a quarterly dividend of $3.99 per share. Monte Rosa Therapeutics, Inc. pays -- of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GLUE or NVS?
Monte Rosa Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Novartis AG quarterly revenues of $13.9B. Monte Rosa Therapeutics, Inc.'s net income of -$27.1M is lower than Novartis AG's net income of $3.9B. Notably, Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio is 56.52x while Novartis AG's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics, Inc. is 7.35x versus 4.84x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLUEMonte Rosa Therapeutics, Inc.7.35x 56.52x $12.8M -$27.1M NVSNovartis AG4.84x 18.24x $13.9B $3.9B
-
Which has Higher Returns GLUE or RCEL?
AVITA Medical, Inc. has a net margin of -212.1% compared to Monte Rosa Therapeutics, Inc.'s net margin of -77.29%. Monte Rosa Therapeutics, Inc.'s return on equity of 8.6% beat AVITA Medical, Inc.'s return on equity of -1112.54%.
Company Gross Margin Earnings Per Share Invested Capital GLUEMonte Rosa Therapeutics, Inc.83.59% -$0.33 $286M RCELAVITA Medical, Inc.81.32% -$0.46 $38.1M -
What do Analysts Say About GLUE or RCEL?
Monte Rosa Therapeutics, Inc. has a consensus price target of $17.20, signalling downside risk potential of -0.35%. On the other hand AVITA Medical, Inc. has an analysts' consensus of $7.92 which suggests that it could grow by 124.65%. Given that AVITA Medical, Inc. has higher upside potential than Monte Rosa Therapeutics, Inc., analysts believe AVITA Medical, Inc. is more attractive than Monte Rosa Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings GLUEMonte Rosa Therapeutics, Inc.5 1 0 RCELAVITA Medical, Inc.3 2 1 -
Is GLUE or RCEL More Risky?
Monte Rosa Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AVITA Medical, Inc. has a beta of 1.658, suggesting its more volatile than the S&P 500 by 65.807%.
-
Which is a Better Dividend Stock GLUE or RCEL?
Monte Rosa Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Monte Rosa Therapeutics, Inc. pays -- of its earnings as a dividend. AVITA Medical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GLUE or RCEL?
Monte Rosa Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than AVITA Medical, Inc. quarterly revenues of $17.1M. Monte Rosa Therapeutics, Inc.'s net income of -$27.1M is lower than AVITA Medical, Inc.'s net income of -$13.2M. Notably, Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio is 56.52x while AVITA Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Monte Rosa Therapeutics, Inc. is 7.35x versus 1.30x for AVITA Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GLUEMonte Rosa Therapeutics, Inc.7.35x 56.52x $12.8M -$27.1M RCELAVITA Medical, Inc.1.30x -- $17.1M -$13.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
